New shot aims to calm severe eczema itch and rash
NCT ID NCT07488065
First seen Mar 30, 2026 · Last updated Jun 09, 2026 · Updated 13 times
Summary
This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The main goals are to check safety and see if the drug can reduce eczema symptoms, like itching and skin redness. About 90 participants will receive either the drug or a placebo injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, 200040, China
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.